1
|
Sammani PKT, Yospanya W, Niwa T, Kohata A, Taguchi H, Kinbara K. Monitoring insulin fibrillation kinetics using chromatographic analysis. Int J Biol Macromol 2024; 275:133660. [PMID: 38969030 DOI: 10.1016/j.ijbiomac.2024.133660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2024] [Revised: 06/21/2024] [Accepted: 07/02/2024] [Indexed: 07/07/2024]
Abstract
Insulin is a small protein widely used to treat patients with diabetes and is a commonly used model for protein fibrillation studies. Under specific conditions, such as low pH and high temperature, insulin monomers aggregate to form fibrils. This aggregation is problematic for manufacturing and storage of insulin. The thioflavin T (ThT) assay is commonly used to study amyloid fibrillation but suffers from several limitations, such as the effect of protein concentration, the size of the amyloid fibrillar bundles, competitive binding, and fibril aggregation, all of which hinder precise quantitative analysis. Here, we present a method for studying the kinetics of insulin fibrillation utilizing ultra-performance liquid chromatography (UPLC). This method enables the quantitative detection of soluble insulin components, including chemically modified components. The formation of a deamidated species could be monitored at the early stage of fibrillation, and this species was likely included in the fibrils. In addition, in the presence of inhibitors known to compete with ThT for binding to fibrils, UPLC analysis showed the disappearance of soluble components even though the ThT assay did not indicate the presence of fibrils. These results suggest that the UPLC-based analysis presented here can complement the ThT assay for investigating the kinetics of protein fibrillation.
Collapse
Affiliation(s)
| | - Wijak Yospanya
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan.
| | - Tatsuya Niwa
- Cell Biology Center, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan
| | - Ai Kohata
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan
| | - Hideki Taguchi
- Cell Biology Center, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan
| | - Kazushi Kinbara
- School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan; Research Center for Autonomous Systems Materialogy (ASMat), Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8501, Japan.
| |
Collapse
|
2
|
Xu R, Jap E, Gubbins B, Hagemeyer CE, Karas JA. Semisynthesis of A6-A11 lactam insulin. J Pept Sci 2024; 30:e3542. [PMID: 37697741 PMCID: PMC10909544 DOI: 10.1002/psc.3542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 08/22/2023] [Accepted: 08/23/2023] [Indexed: 09/13/2023]
Abstract
Insulin replacement therapy is essential for the management of diabetes. However, despite the relative success of this therapeutic strategy, there is still a need to improve glycaemic control and the overall quality of life of patients. This need has driven research into orally available, glucose-responsive and rapid-acting insulins. A key consideration during analogue development is formulation stability, which can be improved via the replacement of insulin's A6-A11 disulfide bond with stable mimetics. Unfortunately, analogues such as these require extensive chemical synthesis to incorporate the nonnative cross-links, which is not a scalable synthetic approach. To address this issue, we demonstrate proof of principle for the semisynthesis of insulin analogues bearing nonnative A6-A11 cystine isosteres. The key feature of our synthetic strategy involves the use of several biosynthetically derived peptide precursors which can be produced at scale cost-effectively and a small, chemically synthesised A6-A11 macrocyclic lactam fragment. Although the assembled A6-A11 lactam insulin possesses poor biological activity in vitro, our synthetic strategy can be applied to other disulfide mimetics that have been shown to improve thermal stability without significantly affecting activity and structure. Moreover, we envisage that this new semisynthetic approach will underpin a new generation of hyperstable proteomimetics.
Collapse
Affiliation(s)
- Rong Xu
- Australian Centre for Blood DiseasesMonash UniversityMelbourneVictoria3004Australia
| | - Edwina Jap
- Australian Centre for Blood DiseasesMonash UniversityMelbourneVictoria3004Australia
| | - Ben Gubbins
- School of ChemistryThe University of MelbourneMelbourneVictoria3010Australia
| | | | - John A. Karas
- School of ChemistryThe University of MelbourneMelbourneVictoria3010Australia
| |
Collapse
|
3
|
Hazra P, Buddha M, Reddy C, Gupta I. Large-scale crystallization as an intermediate processing step in insulin downstream process: explored advantages and identified tool for process intensification. Bioprocess Biosyst Eng 2023; 46:1765-1776. [PMID: 37938390 DOI: 10.1007/s00449-023-02931-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Accepted: 10/04/2023] [Indexed: 11/09/2023]
Abstract
The rising global prevalence of diabetes and increasing demand for insulin, calls for an increase in accessibility and affordability of insulin drugs through efficient and cost-effective manufacturing processes. Often downstream operations become manufacturing bottlenecks while processing a high volume of product. Thus, process integration and intensification play an important role in reducing process steps and time, volume reduction, and lower equipment footprints, which brings additional process efficiencies and lowers the production cost. Manufacturers thrive to optimize existing unit operation to maximize its benefit replacing with simple but different efficient technologies. In this manuscript, the typical property of insulin in forming the pH-dependent zinc-insulin complex is explored. The benefit of zinc chloride precipitation/crystallization has been shown to increase the in-process product purity by reducing the product and process-related impurities. Incorporation of such unit operation in the insulin process has also a clear potential for replacing the high cost involved capture chromatography step. Same time, the reduction in volume of operation, buffer consumption, equipment footprint, and capabilities of product long time storage brings manufacturing flexibility and efficiencies. The data and capabilities of simple operation captured here would be significantly helpful for insulins and other biosimilar manufacturer to make progresses on cost-effective productions.
Collapse
Affiliation(s)
- Partha Hazra
- Biocon Biologics Limited (BBL), Biocon Research Center (BRC), Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Estate, IV Phase, Bommasandra Jigani Link Road, Bangalore, 560 099, India.
| | - Madhavan Buddha
- Biocon Biologics Limited (BBL), Biocon Research Center (BRC), Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Estate, IV Phase, Bommasandra Jigani Link Road, Bangalore, 560 099, India
| | - Chinnappa Reddy
- Biocon Biologics Limited (BBL), Biocon Research Center (BRC), Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Estate, IV Phase, Bommasandra Jigani Link Road, Bangalore, 560 099, India
| | - Indranil Gupta
- Biocon Biologics Limited (BBL), Biocon Research Center (BRC), Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Estate, IV Phase, Bommasandra Jigani Link Road, Bangalore, 560 099, India
| |
Collapse
|
4
|
Andrasi M, Vishwakarma G, Szabo R, Nagy C, Gaspar A. Comparative study on the deamidation of three recombinant human insulins using capillary electrophoresis. J Chromatogr A 2023; 1706:464286. [PMID: 37573758 DOI: 10.1016/j.chroma.2023.464286] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 08/03/2023] [Accepted: 08/06/2023] [Indexed: 08/15/2023]
Abstract
The applicability of capillary zone electrophoresis (CZE) for the separation of different recombinant human insulins and their deamidated isoforms was studied. The high resolving power of CZE is demonstrated by its ability to separate insulin isoforms differing only by 0.984 Da (different-fold deamidated forms) and even components having the exacts same mass but slightly different shapes (same-fold deamidated forms). From among the several insulins available, humulin, glargine and glulisine were selected for our study because their sequences and chemical parameters are quite similar, however, the small differences present in their amino acid sequences influence the deamidation processes. Using a background electrolyte with basic pH was favourable not only for the separation of the different types of insulin but also for the separation of deamidated protein forms even in a bare fused silica capillary. The LOD values ranged between 0.6 - 0.93 mg/L and 2.17 - 4.37 mg/L for UV and ESI-MS detection, respectively. At -20 - -80 °C, the deamidation is minimal, but at temperatures above +5 °C deamidation is accelerated. At +5 °C only 1-fold deamidation forms could be observed for each insulin. Acidified samples incubated for 1-month at room temperature showed varying levels of deamidation: 1-fold, 1-2-fold and 1-2-3-fold forms for glargine, glulisine and humulin, respectively.
Collapse
Affiliation(s)
- M Andrasi
- Department of Inorganic and Analytical Chemistry, University of Debrecen, Egyetem ter 1., Debrecen H-4032, Hungary
| | - G Vishwakarma
- Department of Inorganic and Analytical Chemistry, University of Debrecen, Egyetem ter 1., Debrecen H-4032, Hungary
| | - R Szabo
- Department of Inorganic and Analytical Chemistry, University of Debrecen, Egyetem ter 1., Debrecen H-4032, Hungary
| | - C Nagy
- Department of Inorganic and Analytical Chemistry, University of Debrecen, Egyetem ter 1., Debrecen H-4032, Hungary
| | - A Gaspar
- Department of Inorganic and Analytical Chemistry, University of Debrecen, Egyetem ter 1., Debrecen H-4032, Hungary.
| |
Collapse
|